DrugBiological
Recombinant Super-compound Interferon clinical trials
Keep track of what changes. Save the Recombinant Super-compound Interferon studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Written with another drug
- rSIFN-co
- 3
Studies by the year they started
3 studies that test it; most in 2013 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Sichuan Huiyang Life Science and Technology Corporation (4)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Recombinant Super-compound Interferon is read from its arms, and is right about nine times in ten.
Testing it · 4
- rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal CancerNot yet recruitingPhase 2Sichuan Huiyang Life Science and Technology CorporationNCT07662278Written as Recombinant Super-Compound Interferon (rSIFN-co)
- rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19CompletedPhase 2Sichuan Huiyang Life Science and Technology CorporationNCT05485584Written as rSIFN-co Nasal Spray
- Study of rSIFN-co for Patients With Advanced Solid TumorsTerminatedPhase 1Sichuan Huiyang Life Science and Technology CorporationNCT02464007Written as rSIFN-co
- A Study of rSIFN-co in Subjects With Advanced Solid TumorsCompletedPhase 1Sichuan Huiyang Life Science and Technology CorporationNCT02387307Written as rSIFN-co